Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 04, 2015 7:13 PM ET

Company Overview of University of California, Davis

Company Overview

University of California, Davis operates as an educational and research institution that offers bachelor's, master's, doctoral, first professional, and post bachelor’s degrees. It includes the College of Agricultural and Environmental Sciences, College of Engineering, College of Letters and Science and its professional schools include the Graduate School of Management, School of Education, School of Law, School of Medicine, School of Veterinary Medicine, and the Veterinary Medical Teaching Hospital. University of California - Davis was founded in 1905 and is based in Davis, California. University of California, Davis operates as a subsidiary of University of California System.

One Shields Avenue

Davis, CA 95616

United States

Founded in 1905

Phone:

530-752-1011

Fax:

530-752-6363

Key Executives for University of California, Davis

Interim Provost & Executive Vice Chancellor
Director of Foundation Plant Services, Viticulture Consortium West, and California Competitive Grants for Research in Viticulture and Enology; and Specialist in Cooperative Extension
Visiting Professor
Compensation as of Fiscal Year 2015.

University of California, Davis Key Developments

New York Blood Center Announces New Collaboration with the University of California, Davis to Manufacture Specialized Lines of Stem Cells

New York Blood Center (NYBC) announced a new collaboration with the University of California, Davis, Health System to manufacture specialized lines of stem cells as potential therapies for repair and regeneration of retina, kidney, lung and liver tissue, as well as for the treatment of neurodegenerative disorders such as Parkinson's, Alzheimer's and Huntington's disease. Under the two-year agreement, UC Davis will produce induced pluripotent stem cells (iPSCs) from homozygous units from New York Blood Center's umbilical cord blood bank. Cord blood units contain adult stem cells collected from umbilical cord blood donations after the birth and safe delivery of a baby. NYBC's rare collection of homozygous units presents a unique opportunity to make iPSC lines that will be capable of making any human tissue and being matched to a large number of people. This will allow for vast new opportunities for future clinical use.

University of California, Davis Presents at Macquarie Global Quantative Research Conference, Jul-22-2015 09:00 AM

University of California, Davis Presents at Macquarie Global Quantative Research Conference, Jul-22-2015 09:00 AM. Venue: Hong Kong. Speakers: Roger Edelen, Associate Professor, Graduate School of Management.

OncoSec Medical and University of California, Davis Collaborate to Test Intratumoral Cancer Immunotherapy in Canine Soft Tissue Sarcoma

OncoSec Medical Inc. announced a collaboration with University of California, Davis (UC Davis) School of Veterinary Medicine to test ImmunoPulse™ IL-12 as an immunotherapy in dogs with soft tissue sarcoma. The primary goals of the canine study are to advance the understanding of the mechanism of action of ImmunoPulse™ IL-12 and validate key clinical biomarkers. The study is an open label, neoadjuvant two-arm pilot trial in approximately 12 canines with soft tissue sarcoma. Eligible canine patients will be randomized to receive one of the two experimental ImmunoPulse™ IL-12 treatment schedules, followed by definitive surgical resection of the tumor. OncoSec's core immunotherapy platform, ImmunoPulse™, has been used to deliver DNA-based IL-12 in Phase II clinical trials for metastatic melanoma and Merkel cell carcinoma and plans to initiate Phase II studies in head and neck cancer and triple negative breast cancer.

Similar Private Companies By Industry

Company Name Region
IBQ Systems, Inc. United States
Majestic Safe-T-Products Ltd United States
Twentieth Cheltenham Properties Inc. United States
Spectrum Medical Equipment Inc. United States
IFL Holdings Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact University of California, Davis, please visit www.ucdavis.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.